Elevated triglyceride and cholesterol levels are risk factors for cardiovascular disease and are often associated with diabetes and metabolic syndrome. Recent reports suggest that FGF19 and FGF21 can dramatically improve metabolic dysfunction, including hyperglycemia, hypertriglyceridemia, and hypercholesterolemia. Due to their similar receptor specificities and co-receptor requirements, FGF19 and FGF21 share many common properties and have been thought to be interchangeable in metabolic regulation. Here we directly compared how pharmacological administration of recombinant FGF19 or FGF21 proteins affect metabolism in the B6.V-Lep ob /J leptin deficient mice. FGF19 and FGF21 equally improved glucose parameters, however, we observed increased serum triglyceride and cholesterol levels after treatment with FGF19, but not with FGF21. Increases in serum triglycerides were also observed after a 4-day treatment with FGF19 in C57BL6/J mice on high fat diet. This is in contrast to many literature reports which showed significant improvements in hyperlipidemia after chronic treatment with either FGF19 or FGF21in high fed diet models. We propose that FGF19 has both lipid raising and lipid lowering actions mediated through different FGF receptors and target tissues, and results described here provide a potential mechanism that may explain the inconsistency in the reported effects of FGF19 on lipid metabolism.
Introduction
FGF19 belongs to a distinct subfamily of fibroblast growth factors which play important roles in metabolic regulation [1, 2] . A diminished affinity toward heparan sulfate allows FGF19 to circulate and function as an endocrine hormone [3] . In lieu of heparan sulfate binding, FGF19 requires a protein co-factor, βKlotho, to effectively interact with and activate FGF receptors [4, 5, 6] . The requirement for a co-receptor is a unique feature common to the FGF19 subfamily further exemplified by another subfamily member, FGF21, which also lacks heparan sulfate affinity and utilizes βKlotho as its co-receptor [4] . Consistent with their shared ability to use the same coreceptor for signaling, there is also extensive overlap in the reported pharmacological effects of FGF19 and FGF21. Both FGF19 and FGF21 transgenic mice, as well as chronic administration of either recombinant FGF19 or FGF21 proteins, similarly 4 sequence homology to β-glucosidases in bacteria and plants [10] . βKlotho has a short intracellular domain and is unlikely to signal by itself. Its primary role is believed to mediate interactions between these two FGF molecules and FGF receptors (FGFR) to activate FGFR tyrosine kinase activity [11] . βKlotho interacts with only four of the seven major FGFRs, the "c" isoforms of FGFRs 1-3 and FGFR4 [11] . Both FGF19 and FGF21 can activate FGFR1c, 2c, and 3c complexed with βKlotho in vitro [4, 6, [11] [12] [13] . Recent results using an engineered FGF19 variant with altered receptor specificity biased toward FGFR1c/βKlotho and with novel mimetic proteins that specifically activate only the FGFR1c/βKlotho receptor complex demonstrate the essential role this receptor complex plays in mediating the effects of FGF19 and FGF21 on regulating the glucose and lipid metabolism as well as energy expenditure [14] .
Despite extensive similarities in their in vivo and in vitro pharmacology, differences do exist between FGF19 and FGF21. FGF19 can also signal through FGFR4 but FGF21 cannot [4, 15] . The ability of FGF19 to activate FGFR4, the predominant receptor expressed in the liver, has been linked to its regulation of bile acid homeostasis. It has been proposed that FGF19 is an FXR target gene [16] . Postprandial increases in intestinal bile acid levels activate FXR in intestinal epithelia, which in turn induce expression and secretion of FGF19. FGF19 then acts as the enterohepatic signal to suppress hepatic expression of cholesterol 7α-hydroxylase (CYP7A1), the enzyme by guest, on November 9, 2017 www.jlr.org Downloaded from responsible for the rate limiting step of bile acid synthesis. This occurs in the liver via activation of hepatic FGFR4, hence completing a negative feedback loop on bile acid synthesis [16] . In addition, FGF19 has also been shown to affect expression of other Cyp enzymes which may lead to alterations in bile acid pool composition [17] .
However, given that the elimination of cholesterol is primarily through conversion to bile acids and subsequently excreted, FGF19 treatment would then be expected to not only reduce bile acid levels, but also increase cholesterol levels. In addition, bile acids are also known to affect TG homeostasis, reduction in bile acid levels due to CYP7A1 deficiency or from treatment with bile acid-binding resins in humans lead to elevated TG levels [18, 19, 20, 21] . Therefore, the expected effects of increased cholesterol and TG levels due to reduction or alteration in bile acid pool size and composition by treatment with FGF19 may appear to be inconsistent with the observed reduction of these parameters in FGF19 transgenic mice and in mice treated chronically with recombinant FGF19 protein [8, 22] .
In the present study, we compared the effects FGF19, FGF21, and a variant of FGF19 which only activates FGFR4 had on metabolism in rodent models. Our results revealed a new action of FGF19 and suggest that FGF19 has a dual function in lipid metabolism.
Materials and Methods

Expression and Purification of Recombinant FGF19 and FGF21 proteins.
Recombinant FGF19, FGF21 and FGF19dCTD proteins used in this study were expressed and purified from E. coli as previously described [13, 15] .
Cell Culture, Transfections, and MSD Assay Analysis for FGF Signaling. L6 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and penicillin/streptomycin. Cells were plated, transfected with various FGF receptors using the Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer's protocol and treated with various FGF molecules as previously described [15] . Cells were collected 15 min after treatment, snap frozen in liquid nitrogen, resuspended in lysis buffer, and the total and phosphorylated ERK were measured using an MSD whole cell lysate Phospho-ERK1/2 kit (Meso Scale Discovery) according to the manufacturer's instructions. All experiments were performed in duplicate. were injected intraperitoneally (i.p.) daily at stated concentrations for the duration as indicated. On the last day, mice were fasted for four hours. Dosing of vehicle and proteins occurred one hour prior to baseline glucose measurement. At termination, mice were euthanized, the blood was collected by cardiac puncture and liver tissues were harvested. The bile acid pool size was determined as bile acid content of the liver, the gallbladder, the small intestine and its contents. In the case of CYP7A1 measurements, dosing occurred five hours prior to tissue collection for Fig. 5 and Supplementary Fig. 3 . For data in Supplementary Fig. 1 calculated from the standard curve. Bile acids were measured using the Total Bile Acids Assay Kit (Calorimetric) from BQ Kits, San Diego, according to the manufacturer's instructions. The bile acid pool size was determined from the total extract of liver, gallbladder, and small intestine and its contents, and was expressed as µmole of bile acid/100 g of body weight.
Animals and
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Results
FGF19 treatment unexpectedly increased plasma TG and cholesterol levels in
ob/ob mice. Previous reports described a reduction in plasma TG and cholesterol with chronic FGF19 exposure such as transgenic animals or long term treatment with recombinant protein in high fat diet mice models. However, in our studies to examine the effects of FGF19 on metabolism in the leptin deficient ob/ob mice, we unexpectedly observed increases in plasma TG and cholesterol levels ( Fig. 1) . Ob/ob mice were sorted by body weight and serum glucose levels, then injected intraperitoneally (i.p.) with a PBS control, 1 mg/kg FGF19, or 1 mg/kg FGF21 daily for 7 days. Perhaps due to the relatively short treatment, no significant differences in body weight were observed among the three groups (Fig. 1A) . However, consistent with results from numerous publications, fasting serum glucose levels were significantly reduced in mice injected with either FGF19 or FGF21 as compared to the PBS control group at the end of the 1-week treatment (Fig. 1B ). These data confirmed previous studies that showed FGF19 and FGF21 were nearly interchangeable in terms of glucose metabolism and that activation of FGFR4 by FGF19 did not appear to add benefit toward glucose regulation. This is also consistent with our previous report demonstrating that activation of FGFR4 alone does not improve glucose parameters [15] .
Triglyceride and cholesterol concentrations were also measured at the end of the 1 week study. Surprisingly, mice from the FGF19 treatment group displayed increased serum triglyceride and cholesterol levels after 1-week treatment, whereas the PBS and FGF21 treatments resulted in no change in either of these parameters (Fig. 1C-D) .
FGF19 is known to suppress CYP7A1 expression in the liver through activation of FGFR4. Consistent with this, mice treated with FGF19 displayed reduced liver CYP7A1 expression while no significant changes were observed with FGF21 treatment as FGF21 does not activate FGFR4 ( Supplementary Fig. 1 ).
Serum lipoproteins VLDL, LDL and HDL were separated by size exclusion chromatography and triglyceride and cholesterol content of lipoprotein fractions were quantified (Fig. 2) . In serum from FGF19 treated mice, higher levels of triglyceride were detected in VLDL fractions ( Fig. 2A) . VLDL carries the majority of the triglyceride in serum. Furthermore cholesterol content was increased in all lipoprotein fractions including VLDL, LDL and HDL in the FGF19 treatment group (Fig. 2B ).
To test if the increase in plasma TG observed in the ob/ob model could be resolved in a longer term treatment, a two-week study was carried out with daily injection of 1 mg/kg FGF19 protein in 7-week old male ob/ob mice. Similar to results shown in Figure 1 , FGF19 injection induced significant reduction in plasma glucose levels at both week 1 and week 2 after initiation of the treatment, and there is also a significant improvement in the ability of FGF19 treated mice to dispose glucose in a OGTT test (Fig. 3) . However, similar to the 1-week treatment shown in Figure 1 , FGF19 treatment also increased plasma TG and cholesterol levels at the end of the 2-week treatment ( Fig. 3D and 3E ).
Acute FGF19 treatment also increased plasma TG levels in diet induced obesity (DIO) mice. Since the increase in plasma TG levels we observed post FGF19 treatment was in contrast to the previously reported lowering effects of FGF19 on plasma TG in DIO mice models [8, 17] , we wondered if our observations in ob/ob mice were model specific. In our previous studies in DIO mice, we also reported a reduction in plasma TG levels after daily injection of FGF19 for two weeks [14] .
Therefore, we explored whether there could be a different acute effect of FGF19 on plasma TG levels in the DIO mice.
Male C57BL/6J mice were put on a high fat diet at 4-weeks old. After 14 weeks on the high fat diet, the animals were divided into groups (n=12) based on body weight, glucose and triglyceride. Mice were then IP-injected daily with PBS or 1mg/kg FGF19 for a total of 10 days. Body weight and glucose were measured. Serum samples were collected by tail bleeding for measuring triglyceride and total cholesterol level. As shown in Figure 4 , in this study, FGF19 treatment did not induce significant body weight changes and induced a trend (with one significant time point) in reducing fasting plasma glucose levels during the treatment (Fig. 4A and 4B ). Insulin levels were significantly reduced with the FGF19 treated group indicating improvements in insulin sensitivity (Fig. 4C ). Similar to ob/ob mice, the FGF19 treatment induced a significant increase in plasma TG levels, however, only transiently. The increase peaked at day 4 post start of FGF19 injection and returned to no significance by day 10 (Fig. 4D) . Cholesterol levels were not significantly affected at these time points (Supplementary Figure 2) . These results suggest that the observed increase in plasma TG levels by FGF19 treatment is perhaps not model specific.
Selective activation of liver FGFR4 increased plasma TG and cholesterol levels without affecting glucose metabolism. Bile acid metabolism can affect triglyceride and cholesterol homeostasis, therefore, we wanted to determine if the observed increase in TG and total cholesterol with FGF19 treatment could be at least in part due to its ability to regulate bile acid production via activation of liver FGFR4. We previously generated an FGF19 variant, FGF19dCTD, that selectively activates FGFR4 but not FGFRs1c, 2c, or 3c [ Fig. 5A, 15 ]. This molecule allowed us to isolate FGFR4 activation and assess its regulation of bile acid, TG, and cholesterol metabolism without interference from simultaneous activation of other FGFRs.
Similar to the experiment described in Fig. 1 , no significant differences in body weight were observed in ob/ob mice treated with 5 mg/kg FGF19 or 5 mg/kg FGF19dCTD daily for 7 days as compared to the PBS vehicle group (Fig. 5B) . However, in contrast 14 to treatment with FGF19 or FGF21, FGF19dCTD did not display reduced plasma glucose levels (Fig. 5C ). This is consistent with our previous study [15] and suggests that activation of FGFR4 alone is not sufficient to improve glucose metabolism.
Consistent with its ability to activate FGFR4, FGF19dCTD treatment inhibited liver CYP7A1 expression and reduced bile acid pool size similar to native FGF19 (Fig. 5D & 5E, Supplementary Figure 3) . Interestingly, like native FGF19, treatment with FGF19dCTD also increased plasma TG and total cholesterol levels ( Fig. 5F and 5G ).
Therefore, selective activation of FGFR4 by FGF19dCTD separated FGF19's effects on lipid metabolism from its regulation of glucose metabolism, indicating that FGFR4 is primarily responsible for the inhibition of bile acid production and increased TG and total cholesterol levels associated with FGF19 treatment over the 7-day study.
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Discussion
Bile acid metabolism can affect triglyceride and cholesterol homeostasis. It has been shown that bile acid treatment reduces serum triglyceride concentrations through activation of FXR [23] and bile acid-binding resins increase VLDL triglyceride content [20] . Furthermore, addition of bile acids to cultured rat and human hepatocytes decreased VLDL secretion [24] , indicating a reciprocal relationship between the bile acid pool and triglyceride content. Bile acid is also the end product of cholesterol catabolism. A great proportion of hepatic cholesterol is used in bile acid synthesis catalyzed by CYP7A1, and thus, deficiency in CYP7A1 leads to elevated total cholesterol [21] . Therefore, inhibition of bile acid synthesis would be expected to cause an increase in plasma TG and cholesterol levels.
FGF19 is a unique endocrine FGF molecule and its effects on bile acid metabolism have been well established. FGF19 activates FGFR4 which is predominantly expressed in the liver, and activation of this receptor by FGF19 has been shown to reduce the bile acid pool size [16, 25] and affect bile acid composition [17] . This pathway has been proposed as the enterohepatic signal that mediates postprandial inhibition of bile acid synthesis [16, 25] . Given the connections between bile acid, TG, and cholesterol homeostasis as discussed above, FGF19 treatment would also be expected to increase plasma TG and cholesterol levels. This is what we observed in our study. Treatment with FGF19 for 7-days in the ob/ob mouse model caused a reduction in bile acid and plasma glucose levels, and an increase in both TG and total cholesterol levels ( Fig. 1, 2 , and 5). A variant of FGF19, FGF19dCTD, which specifically activates only FGFR4, recapitulated FGF19's effects on bile acids, TG, and cholesterol levels but, distinct from FGF19, was devoid of effect on glucose (Fig.   5 ). This confirms that the FGF19 induced changes in lipid profile is due to activation of liver FGFR4, while glucose regulation is mediated through a different FGFR. FGF21 is a unique FGF molecule that belongs to the same subfamily as FGF19 [26] . FGF21, including improvement of hyperglycemia and hyperlipidemia [14, 28] . These effects were absent in lipoatrophic animals [28] , suggesting FGFR1 in adipose tissue is the main target of FGF21 action. Activation of FGFR1 in adipose tissue causes increases in metabolic rate and energy expenditure, partly due to brown adipose tissue activation [28] . The observed improvement in hyperlipidemia may result from a combination of directly increased LDL receptor expression in hepatocytes [29] , and perhaps indirectly through increased energy expenditure. The increased mobilization of lipids through oxidative metabolism [22, 28] may lead to lower lipid content in both liver and plasma.
The metabolic effects of FGF19 and FGF21 are often thought to be interchangeable.
However, our study shows that FGF19 can raise serum triglyceride and cholesterol concentrations in pharmacological studies at supraphysiological levels, but not FGF21.
In retrospect, this is not surprising because the receptor specificities of these two molecules are not identical. Only, FGF19 can activate FGFR4 in the liver and suppress bile acid synthesis. Therefore, to reconcile increased plasma TG and cholesterol levels we observed following FGF19 treatment with the hypolipidemic effects previously reported, we believe FGF19 has two opposing actions on lipid metabolism: one lipid raising action mediated through the activation of FGFR4 and modulation of bile acid synthesis in the liver, and a second lipid lowering action through FGFR1c, primarily in adipose and perhaps other non-hepatic tissues (Fig. 6 ).
Lipid homeostasis thus results from the combination of these two actions. The kinetics of these two actions may be different. FGFR4 mediated CYP7A1 suppression can be observed within hours after FGF19 treatment [15] , whereas increased metabolic rate may take longer to manifest. Prior studies in DIO mice may have missed this observation because measurements of serum lipids were made only after chronic treatment. At this point body lipid content may have already decreased due to increased energy expenditure along with increased uptake and subsequent metabolism through alternative pathways. Therefore, the lipid lowering action of FGF19 became predominant over the opposing lipid raising action in these studies. In contrast, with the short duration of treatment with FGF19, the lipid raising action played a more dominant role due to its faster kinetics. This is seen in our study in DIO mice where the TG increase was seen only on day 4 and to a lesser extent on day 7 then returned to baseline (Fig. 4C) . The exact mechanism for the TG increase is presently unclear, it is possible that this is mediated through FXR or other bile acid receptors by the alteration in bile acid pool composition or size. However, our findings do appear to resolve the inconsistency between the observed hypolipidemic effects upon long term FGF19 treatment, as well as expected hyperlipidemic effects from FGF19 action on liver bile acid metabolism. Interestingly, ob/ob mice seem more sensitive to the hyperlipidemic effects of FGF19 as the plasma TG and cholesterol levels remained elevated even two weeks post FGF19 treatment (Fig. 3) . Recent results suggest that although leptin is not required for FGF21's anti-diabetic actions, leptin may exert additive or synergistic effects to FGF21 on glucose and body weight lowering and restores FGF21 sensitivity in lipodystrophyic mice [30] . Whether there is also a cross talk between FGF19 and leptin pathways and whether leptin deficiency exacerbates the hyperlipidemic effects of FGF19 will be an interesting question to further explore in the future.
In conclusion, due to its ability to specifically activate multiple FGF receptors, FGF19
can have two separate and opposite effects on lipid metabolism. Unlike previous studies which suggested that FGF19 might be solely beneficial for treatment of hyperlipidemia, our data reveal another consequence of FGF19 action on lipid metabolism. By comparison, lacking an ability to signal through FGFR4, FGF21 is probably a "cleaner" molecule with regard to both glucose and lipid metabolism. Figure 6 by guest, on November 9, 2017 www.jlr.org
